Tackling nicotine dependence through data-driven innovation

Credera Team

Tackling nicotine dependence through data-driven innovation

Over 29 million U.S. adults still smoke, making it the leading cause of preventable death in America. That's why Credera is proud to be part of Omnicom's cross-agency team partnering with Achieve Life Sciences on their groundbreaking cytisinicline launch, a potentially transformational nicotine dependence treatment.

This isn't just another product launch. It's technology with purpose.

‘One team, powered by many’

The launch strategy will incorporate generative AI, predictive analytics, and social listening to enhance targeting and personalization, alongside partnerships with healthcare apps, pharmacies, and data providers.  

What makes this approach particularly powerful is its integrated nature. The Credera team is helping develop an AI-enabled marketing technology platform that solves real problems for real people. Working alongside our Omnicom partners at Goodby, Silverstein & Partners, DDB Health, and Ketchum Health, we're building solutions that transform how healthcare innovations reach those who need them most.

The cross-functional team—which spans consumer branding, medical education, and PR—suggests a holistic commercialization strategy that will create personalized pathways to connect treatment options with those most likely to benefit.

That strategy will incorporate generative AI, predictive analytics, and social listening to enhance targeting and personalization, and leverage partnerships with healthcare apps, pharmacies, and data providers.

Regarding Credera’s role in the project, Achieve’s press release states:

 "What stands out is the data-driven, technology-focused approach led by Omnicom's Credera unit. This strategy diverges from traditional pharma launch playbooks, which typically rely heavily on sales force deployment with less sophisticated targeting. By leveraging AI-enabled marketing technology and predictive analytics, Achieve can potentially optimize resource allocation and enhance ROI – critical for a small biopharma launching its first product."

What’s next?

As Achieve Life Sciences progresses through the regulatory approval process following their June 25, 2025, NDA submission, our team continues refining the platform that will support this important public health initiative.

By pairing their scientific innovation with our technological capabilities, Achieve is positioning themselves to compete effectively against established players.  

Read the full press release.

About Credera

Credera, a global consulting firm, helps clients unlock potential in a complex and competitive digital world. We drive exceptional, industry-tailored experiences and solutions in transformation, MarTech, AI, and technology. As a values-led organization, our teams take an authentic approach through humility and excellence. We believe this approach has allowed us to work with and transform the most influential brands and organizations in the world, from strategy through to execution. Visit us at www.credera.com.